Melatonin in Chagas' disease. Possible therapeutic value

Area of Science:

• Tropical medicine
• Immunology
• Pharmacology

Background:

• Chagas disease, caused by Trypanosoma cruzi, is a major health issue in Latin America, leading to significant mortality and morbidity.
• Chronic Chagas disease affects 25-30% of infected individuals, often resulting in severe cardiac complications.
• Effective control of T. cruzi infection requires a robust immune response, including nitric oxide (NO) production by macrophages.

Purpose of the Study:

• To investigate a potential novel add-on treatment strategy for Chagas disease.
• To explore the combined therapeutic effects of melatonin and a melatonin agonist (ramelteon) in managing T. cruzi infection.
• To assess the potential of this combination therapy to reduce parasitemia and mitigate chronic disease progression, particularly cardiomyopathy.

Main Methods:

• The study hypothesizes a coordinated administration approach.
• Utilizing a melatonin agonist (ramelteon) during the acute phase to potentially manage parasitemia without affecting NO production.
• Administering melatonin during the chronic phase to combat oxidative stress and preserve mitochondrial function, thereby preventing cardiomyopathy.

Main Results:

• Melatonin's role in T. cruzi infection is complex, potentially promoting infection but also reducing parasitemia and NO production at high doses during the acute phase.
• Sustained oxidative stress and myocardial damage characterize the chronic phase of Chagas disease.
• The proposed combination therapy aims to leverage the distinct properties of ramelteon and melatonin for synergistic therapeutic benefits.

Conclusions:

• A coordinated administration of ramelteon and melatonin presents a novel therapeutic hypothesis for Chagas disease.
• This strategy could potentially address both the acute parasitic load and the chronic cardiac sequelae.
• Further research is warranted to validate this combination therapy as an effective add-on treatment for Chagas disease.